Ketamine and MDMA Research Updates
Ketamine Psychedelic Therapy
Leningrad Regional Center for Alcoholism and Drug Addiction Therapy
Evgeny Krupitsky, M.D., Ph.D.
So far, our research team has treated 68 heroin addicts as part of a three-year study of ketamine psychotherapy (KPT). This study is being funded by MAPS and the Heffter Research Institute.
In June 1998, I presented a paper at the International Satellite Meeting "Building International Research on Drug Abuse" held in Scottsdale, Arizona. This meeting was organised by the National Institute on Drug Abuse (NIDA) in conjunction with the 60th Annual Meeting of the College on Problems of Drug Dependence (CPDD), the major conference in the U.S. (and in the world) focused on the problems of drug addiction.
The presentation raised a lot of interest among participants and even among some NIDA officials who noted that KPT could be a useful approach to the treatment of heroin addiction, particularly in those countries where methadone maintenence is not available. In spite of the fact that the mainstream psychiatric paradigm dominated at the NIDA/CPDD Meeting, there were many reseachers there who felt positive about the perspectives of psychedelic psychotherapy in the field of addiction. In particular, I had a very interesting and productive dicussion with Dr. Kenneth Alper of the Neuropsychiatry Center of New York University School of Medicine and with Dr. John Halpern of the Alcohol and Drug Abuse Research Center of Harvard Medical School. I hope that we will be able to do collaborative research with ketamine as a result of our discussions in Arizona.
I would like to express my deepest gratitude to MAPS which covered my hotel expenses in Scottsdale and to NIDA which covered my travel expenses from St. Petersburg to Arizona. Without their support I would not be able to attend the NIDA/CPDD Meeting because of the very poor economic situation in Russia, particularly in the area of medical science, which is almost out of Federal funding at the moment.
MDMA Research Updates
Serotonin and dopamine system interactions
in the reinforcing properties of psychostimulants
Wayne State University School of Medicine
Principal Investigator: Manuel E. Tancer, M.D.
This study began in September 1998 (see MAPS Bulletin Vol. VII No. 3, Summer 1997). A low dose (75 mg) of MDMA has been administered to subjects as part of the dose-finding phase.
MDMA Pharmacokinetics Study at UC San Francisco
Principal Investigator: John Mendelson, M.D.
The MDMA administration phase of this study has been
completed. Data analysis is underway.